Clonal heterogeneity and tumor evolution inform treatment resistance in a patient with HER2+breast cancer

被引：0
|
作者：
Buendia-Buendia, Jorge E. [1 ]
Pernas, Sonia [2 ]
Cohen, Ofir [1 ]
Mao, Ping Ping [2 ]
Kowalski, Kailey [2 ]
Lin, Nancy [2 ]
Winer, Eric [2 ]
Wagle, Nikhil [2 ]
机构：
[1] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P3-01-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-01-09
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Heterogeneity in treatment outcomes for HER2+breast cancer - Clinical management strategies
    Tolaney, S.
    CANCER RESEARCH, 2022, 82 (04)
  • [2] HER2+breast cancer
    Hicks, David G.
    Kulkarni, Swati
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (02) : 263 - 273
  • [3] Treatment of ER+/HER2+breast cancer
    Johnston, Stephen
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Molecular heterogeneity in HER2+breast cancer - can outcomes be predicted?
    Prat, A.
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Mevalonate pathway mediates acquired anti-HER2 treatment resistance in HER2+breast cancer
    Hu, Huizhong
    Simon, Lukas
    Qin, Lanfang
    Nardone, Agostina
    Shaw, Chad
    Chamness, Gary
    Heiser, Laura
    Wang, Nicholas
    Gray, Joe W.
    Osborne, C. Kent
    Schiff, Rachel
    CANCER RESEARCH, 2015, 75
  • [6] Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+Breast Cancer
    Kazerouni, Anum S.
    Hormuth, David A., II
    Davis, Tessa
    Bloom, Meghan J.
    Mounho, Sarah
    Rahman, Gibraan
    Virostko, John
    Yankeelov, Thomas E.
    Sorace, Anna G.
    CANCERS, 2022, 14 (07)
  • [7] Quantitative in vivo imaging of intratumoral heterogeneity to assess tumor response to trastuzumab treatment in a preclinical model of HER2+breast cancer
    Syed, A.
    Quarles, C. C.
    McIntyre, J. O.
    Barnes, S. L.
    Yankeelov, T. E.
    Sorace, A. G.
    CANCER RESEARCH, 2017, 77
  • [8] Identification of a neoantigen targeted by tumor-infiltrating lymphocytes in a patient with Her2+breast cancer
    Reimann, H.
    Nguyen, A.
    Huebner, H.
    Erber, R.
    Bausenwein, J.
    Van der Meijden, E. D.
    Lux, M. P.
    Jud, S.
    Griffioen, M.
    Rauh, C.
    Sanborn, J. Z.
    Benz, S. C.
    Rabizadeh, S.
    Beckmann, M. W.
    Mackensen, A.
    Ruebner, M.
    Fasching, P. A.
    Kremer, A. N.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Identification of a neoantigen targeted by tumor-infiltrating lymphocytes in a patient with Her2+breast cancer
    Reimann, H.
    Nguyen, A.
    Huebner, H.
    Erber, R.
    Bausenwein, J.
    Van der Meijden, E. D.
    Lux, M. P.
    Jud, S.
    Griffioen, M.
    Rauh, C.
    Sanborn, J. Z.
    Benz, S. C.
    Rabizadeh, S.
    Beckmann, M. W.
    Mackensen, A.
    Ruebner, M.
    Fasching, P.
    Kremer, A. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 248 - 248
  • [10] Genomics of HER2+breast cancer
    Perou, C.
    CANCER RESEARCH, 2022, 82 (04)
12345